A Comparison of Bone Scan Using between F-18 NaF PET/CT and Tc-99m MDP
DOI:
https://doi.org/10.46475/aseanjr.v19i2.25Keywords:
Bone scan, F-18 NaF PET/CT, Tc-99m MDP, bone metastases.Abstract
Objective: To study bone scintigraphy using between F-18 NaF PET/CT and Tc-99m MDP scan for detecting bone metastases.
Material and Methods: Thirteen patients (5 males, mean age 55.4 years, range 34-74 years) who were suspected bone metastases with single or two equivocal lesions on Tc-99m MDP bone scan were recruited between October 2010 and October 2012. All these patients underwent F-18 NaF PET/CT scan within one week after Tc-99m MDP bone scan. The sensitivity, specificity and accuracy of Tc-99m MDP bone scan and F-18 NaF PET/CT in differentiating metastatic bone lesion from benign lesion by patientbased and lesion-based analyses were studied.
Results: F-18 NaF PET/CT could identify all seven patients with malignant bone metastases that Tc-99m MDP bone scan was interpreted as malignancy in only three patients (42.9%) and equivocal in the rest of these patients. For lesion-based analysis of the overall 75 lesions, the sensitivity, specificity and accuracy of Tc-99m MDP bone scan were 48%, 83.3% and 70.7% and F-18 NaF PET/CT were 100% for all parameters. Besides the ability of F-18 NaF PET/CT to accurately identify malignancy from benign lesion, unenhanced CT portion of PET/CT can show extra-osseous findings that may change patient management.
Conclusion: F-18 NaF PET/CT provides an excellent bone image quality and higher accuracy than Tc-99m MDP bone scan. Then F-18 NaF PET/CT is a good choice for evaluating bone metastases.
Downloads
Metrics
References
Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 1999;40:1623-9.
Blau M, Nagler W, Bender MA. A new isotope for bone scanning. J Nucl Med 1962;3:332-4.
Bridges RL, Wiley CR, Christian JC, Strohm AP. An introduction to Na18F bone scintigraphy: basic principles, advanced imaging concepts, and case examples. J Nucl Med Technol 2007;35:64-76.
Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves TS. Skeletal PET with 18F-floride: Applying new technology to an old tracer. J Nucl Med 2008;49:68-78.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lernan H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP plananr bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287-97.
Chua S, Gnanasegaran G, Cook GJR. Miscellaneous cancer (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39:416-30.
Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18Ffluoride PET/CT bone scan 1.0. J Nucl Med 2010;51:1813-20.
Chen CJ, Ma SY. Prevalence of clinically significant extraosseous findings on unenhanced CT portions of 18F-fluoride PET/CT bone scan. The scientific World Journal [Online]. 2012 [cited 2012 Dec 5]; Available from:httpwww.hindawi.com/journals/tswj/2012/979867.pdf.
Mckillop JH. Bone scanning in metastatic disease. In: Fogelman I, editor. Bone scanning in clinical practice. London: Springer-Verlag; 1987, p. 41-60.
Tumeh SS, Beadle G, Kaplan WD. Clinical significance of solitary rib lesions in patients with extraskeletal malignancy. J Nucl Med 1985;26:1140-3.
McNeil BJ. Value of bone scanning and malignant disease. Semin Nucl Med 1984;14:277-86.
Durning P, Best JJK, Sellwood RA. Recognition of metastatic bone disease in cancer of the breast by computed tomography. Clin Oncol 1983;9:943-6.
Muindi J, Coombes RC, Golding S, Parboo TJ, Khan O, Husband J. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol 1983;56:233-6
Downloads
Published
How to Cite
Issue
Section
License
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)